Search Results - "Strumph, Paul"

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor by Lapuerta, Pablo, Zambrowicz, Brian, Strumph, Paul, Sands, Arthur

“…The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes. Development of SGLT2 inhibitors…”
Get more information

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes by Sands, Arthur T, Zambrowicz, Brian P, Rosenstock, Julio, Lapuerta, Pablo, Bode, Bruce W, Garg, Satish K, Buse, John B, Banks, Phillip, Heptulla, Rubina, Rendell, Marc, Cefalu, William T, Strumph, Paul

“…To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1…”
Get full text

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2 by Rodbard, Helena W., Giaccari, Andrea, Lajara, Rosemarie, Stewart, John, Strumph, Paul S., Oliveira, Juliana, Lapuerta, Pablo, Castro, Rita

“…Aim To evaluate whether the addition of sotagliflozin to optimized insulin significantly increases the proportion of adults with type 1 diabetes who achieve…”
Get full text

LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion by Zambrowicz, Brian, PhD, Lapuerta, Pablo, MD, Strumph, Paul, MD, Banks, Phillip, MS, FRS, Wilson, Alan, PhD, Ogbaa, Ike, MD, Sands, Arthur, MD, PhD, Powell, David, MD

“…Abstract Purpose We sought to assess the efficacy and safety profile of LX4211, a dual inhibitor of sodium-glucose cotransporter1 (SGLT1) and SGLT2, in…”
Get full text

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes by Garg, Satish K, Henry, Robert R, Banks, Phillip, Buse, John B, Davies, Melanie J, Fulcher, Gregory R, Pozzilli, Paolo, Gesty-Palmer, Diane, Lapuerta, Pablo, Simó, Rafael, Danne, Thomas, McGuire, Darren K, Kushner, Jake A, Peters, Anne, Strumph, Paul

“…In this trial in patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0%…”
Get full text

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption by Powell, David R, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo

“…Abstract Context The effect of sotagliflozin (a dual sodium–glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been…”
Get full text

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program by Danne, Thomas, Cariou, Bertrand, Buse, John B, Garg, Satish K, Rosenstock, Julio, Banks, Phillip, Kushner, Jake A, McGuire, Darren K, Peters, Anne L, Sawhney, Sangeeta, Strumph, Paul

“…To evaluate effects of the dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibitor sotagliflozin in combination with insulin on glucose time in range…”
Get full text

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study by Buse, John B, Garg, Satish K, Rosenstock, Julio, Bailey, Timothy S, Banks, Phillip, Bode, Bruce W, Danne, Thomas, Kushner, Jake A, Lane, Wendy S, Lapuerta, Pablo, McGuire, Darren K, Peters, Anne L, Reed, John, Sawhney, Sangeeta, Strumph, Paul

“…Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in…”
Get full text

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study by Bode, Bruce W, Cengiz, Eda, Wadwa, R Paul, Banks, Phillip, Danne, Thomas, Kushner, Jake A, McGuire, Darren K, Peters, Anne L, Strumph, Paul, Sawhney, Sangeeta

“…Young adults with type 1 diabetes (T1D) tend to have higher A1C than older adults and are at increased risk for diabetic ketoacidosis (DKA). Oral adjuncts to…”
Get more information

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial by Baker, Claire, Wason, Suman, Banks, Phillip, Sawhney, Sangeeta, Chang, Anna, Danne, Thomas, Gesty‐Palmer, Diane, Kushner, Jake A., McGuire, Darren K., Mikell, Frank, O'Neill, Mark, Peters, Anne L., Strumph, Paul

“…Aims To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D)…”
Get full text

HbA^sub 1c^ and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study by Danne, Thomas, Cariou, Bertrand, Banks, Phillip, Brandle, Michael, Brath, Helmut, Franek, Edward, Kushner, Jake A, Lapuerta, Pablo, McGuire, Darren K, Peters, Anne L, Sawhney, Sangeeta, Strumph, Paul

“…OBJECTIVE The objective of this study was to evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 and 2 inhibitor sotagliflozin compared…”
Get full text

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2) by DANNE, THOMAS, CARIOU, BERTRAND, BUSE, JOHN B., GARG, SATISH K., ROSENSTOCK, JULIO, BANKS, PHILLIP L., KUSHNER, JAKE A., MCGUIRE, DARREN K., PETERS, ANNE L., SAWHNEY, SANGEETA, STRUMPH, PAUL

“…Sotagliflozin (SOTA) is a dual SGLT1 and SGLT2 inhibitor in development as an adjunct to insulin in T1D. This was a pooled analysis of the inTandem1 and…”
Get full text

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study) by DANNE, THOMAS, CARIOU, BERTRAND, BANKS, PHILLIP L., BRANDLE, MICHAEL, BRATH, HELMUT, FRANEK, EDWARD, KUSHNER, JAKE A., LAPUERTA, PABLO, MCGUIRE, DARREN K., PETERS, ANNE L., SAWHNEY, SANGEETA, STRUMPH, PAUL

“…Sotagliflozin (SOTA) is a dual SGLT1 and SGLT2 inhibitor in development as adjunct therapy to insulin in T1D. In this double-blind, 52-week study, 782 adults…”
Get full text

Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D by PETTUS, JEREMY, WEINZIMER, STUART A., MCCRIMMON, RORY J., AMPUDIA BLASCO, FRANCISCO JAVIER, STEWART, JOHN A., STRUMPH, PAUL, OLIVEIRA, JULIANA H., LAPUERTA, PABLO, CASTRO, RITA

“…In most patients with T1D, adequate glycemic control is not achieved with insulin therapy alone, and intensifying insulin therapy can increase the risk of…”
Get full text

Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes by Gogtay, Nithya J, Bose, Debdipta, Thatte, Urmila M, Conte, Caterina, Secchi, Antonio, Napoli, Nicola, Doumas, Michael, Imprialos, Konstantinos P, Stavropoulos, Konstantinos, Khoo, Teck K, Olson, Kristin M, Garg, Satish K, Strumph, Paul

“…To the Editor: Garg et al. (Dec. 14 issue) 1 report the superiority of adding sotagliflozin, an oral inhibitor of sodium–glucose cotransporters 1 and 2…”
Get full text

FRI604 Stem-cell Derived Islets For Treating Diabetes by Rust, William L, Dalal, Pankaj M, Koval, Anatoliy P, Ratiu, Jeremy J, Southard, Sheryl M, Sumner Strumph, Paul, Welsch, Carole A

“…Abstract Disclosure: W.L. Rust: Employee; Self; Seraxis Inc. Stock Owner; Self; Seraxis Inc. P.M. Dalal: Employee; Self; Seraxis Inc. Stock Owner; Self;…”
Get full text

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study by Danne, Thomas, Cariou, Bertrand, Banks, Phillip, Brandle, Michael, Brath, Helmut, Franek, Edward, Kushner, Jake A., Lapuerta, Pablo, McGuire, Darren K., Peters, Anne L., Sawhney, Sangeeta, Strumph, Paul

“…OBJECTIVE The objective of this study was to evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 and 2 inhibitor sotagliflozin compared…”
Get full text

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12weeks: The inTandem4 trial by Baker, Claire, Wason, Suman, Banks, Phillip, Sawhney, Sangeeta, Chang, Anna, Danne, Thomas, Diane Gesty‐Palmer, Kushner, Jake A, McGuire, Darren K, Mikell, Frank, O'Neill, Mark, Peters, Anne L, Strumph, Paul

“…AimsTo assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D).Materials…”
Get full text

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) by BUSE, JOHN B., GARG, SATISH K., ROSENSTOCK, JULIO, BAILEY, TIMOTHY S., BANKS, PHILLIP L., BODE, BRUCE W., DANNE, THOMAS, KUSHNER, JAKE A., LANE, WENDY, LAPUERTA, PABLO, MCGUIRE, DARREN K., PETERS, ANNE L., REED, JOHN H., SAWHNEY, SANGEETA, STRUMPH, PAUL

“…Sotagliflozin (SOTA) is a dual SGLT1 and SGLT2 inhibitor in development as adjunct therapy to insulin in T1D. In this double-blind, 52-week North American…”
Get full text

Abstract 11267: LX4211, a Dual Inhibitor of Sodium-Glucose Cotransporters 1 and 2, Reduces Systolic Blood Pressure in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment by Lapuerta, Pablo, Strumph, Paul, Banks, Philip, Ogbaa, Ikenna, Zambrowicz, Brian, Sands, Arthur

“…Abstract only Introduction: Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors target only the kidney, and they have reduced efficacy when patients…”
Get full text